December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

12.95 -0.05 (-0.42%)
Streaming Delayed Price Updated: 2:40 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SELLAS Life Sciences Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
SELLAS Stock Hits New Highs: What's Happening Today? ↗
SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares are pushing higher Friday morning, extending Thursday’s strong rally. 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum ↗
Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded. 
Via Stocktwits
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗
Via Stocktwits
News headline image
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial ↗
The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups. 
Via Stocktwits
News headline image
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail ↗
Shkreli argued that the company lacks a clear mechanism of action and strong clinical data. 
Via Stocktwits
News headline image
Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗
Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout ↗
The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve. 
Via Stocktwits
News headline image
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout ↗
The stock's recent surge has been driven by anticipation around the late-stage Regal trial evaluating its leukemia therapy Galinpepimut-S (GPS). 
Via Stocktwits
News headline image
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout ↗
Short interest has risen about 15% since the December update on the Phase 3 Regal trial. 
Via Stocktwits
News headline image
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside ↗
The rally comes ahead of results from the Phase 3 Regal trial testing Galinpepimut-S (GPS) as a maintenance treatment for AML patients. 
Via Stocktwits
News headline image
SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest? ↗
SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage... 
Via Stocktwits
Topics Death
News headline image
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% ↗
According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours. 
Via Stocktwits
Topics Regulatory Compliance
News headline image
SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗
The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population. 
Via Stocktwits
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗
Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B ↗
SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours. 
Via Stocktwits
Topics Death
News headline image
Why Is SLS Stock Drawing Significant Investor Attention Today? ↗
Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the... 
Via Stocktwits
Topics Death
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗
The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. 
Via Stocktwits
Topics Death
News headline image
SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗
Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 
Via Stocktwits
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗
The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest. 
Via Stocktwits
Topics Death
News headline image
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗
The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News ↗
Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.